Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1920 1
1943 1
1947 12
1948 10
1949 15
1950 31
1951 44
1952 46
1953 47
1954 37
1955 65
1956 42
1957 61
1958 45
1959 11
1960 2
1962 1
1963 42
1964 61
1965 51
1966 54
1967 41
1968 58
1969 49
1970 31
1971 23
1972 20
1973 13
1974 31
1975 20
1976 21
1977 36
1978 19
1979 39
1980 35
1981 28
1982 32
1983 38
1984 28
1985 29
1986 33
1987 38
1988 37
1989 42
1990 44
1991 54
1992 40
1993 30
1994 32
1995 31
1996 31
1997 39
1998 39
1999 35
2000 40
2001 44
2002 53
2003 53
2004 40
2005 79
2006 63
2007 53
2008 86
2009 72
2010 94
2011 99
2012 69
2013 110
2014 95
2015 99
2016 123
2017 138
2018 133
2019 135
2020 213
2021 227
2022 254
2023 246
2024 95

Text availability

Article attribute

Article type

Publication date

Search Results

4,226 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Phaibulputhipong
Page 1
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Mirza MR, González-Martín A, Graybill WS, O'Malley DM, Gaba L, Stephanie Yap OW, Guerra EM, Rose PG, Baurain JF, Ghamande SA, Denys H, Prendergast E, Pisano C, Follana P, Baumann K, Calvert PM, Korach J, Li Y, Malinowska IA, Gupta D, Monk BJ. Mirza MR, et al. Cancer. 2023 Jun 15;129(12):1846-1855. doi: 10.1002/cncr.34706. Epub 2023 Apr 14. Cancer. 2023. PMID: 37060236 Clinical Trial.
BACKGROUND: The PRIMA/ENGOT-OV26/GOG-3012 (NCT02655016) trial was amended to prospectively evaluate the safety and efficacy of an individualized starting dose (ISD) regimen of niraparib for first-line maintenance therapy in patients with newly diagnosed advanced ovarian ca …
BACKGROUND: The PRIMA/ENGOT-OV26/GOG-3012 (NCT02655016) trial was amended to prospectively evaluate the safety and efficacy of an ind …
PRIMA, non nocere.
Harvin JA, Kao LS. Harvin JA, et al. Lancet. 2017 Aug 5;390(10094):535-536. doi: 10.1016/S0140-6736(17)31616-1. Epub 2017 Jun 20. Lancet. 2017. PMID: 28641874 No abstract available.
Prima-1 and APR-246 in Cancer Therapy.
Zatloukalová P, Galoczová M, Vojtěšek B. Zatloukalová P, et al. Klin Onkol. 2018 Winter;31(Suppl 2):71-76. doi: 10.14735/amko20182S71. Klin Onkol. 2018. PMID: 31023027 Review. English.
Reactivation leads to the initiation of apoptosis followed by the suppression of the malignant phenotype. Prima-1 and its methylated form Prima-1Met (also called APR-246) are compounds capable of reactivating mutated p53. ...In addition to p53 reactivation itself, t …
Reactivation leads to the initiation of apoptosis followed by the suppression of the malignant phenotype. Prima-1 and its methylated …
Prima facie.
Ville Y. Ville Y. Ultrasound Obstet Gynecol. 2010 Jan;35(1):1-3. doi: 10.1002/uog.7526. Ultrasound Obstet Gynecol. 2010. PMID: 20033992 Free article. No abstract available.
Endophytes: Improving Plant Performance.
Fagorzi C, Mengoni A. Fagorzi C, et al. Microorganisms. 2022 Sep 3;10(9):1777. doi: 10.3390/microorganisms10091777. Microorganisms. 2022. PMID: 36144379 Free PMC article.
Antitumor Effects of PRIMA-1 and PRIMA-1(Met) (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?
Menichini P, Monti P, Speciale A, Cutrona G, Matis S, Fais F, Taiana E, Neri A, Bomben R, Gentile M, Gattei V, Ferrarini M, Morabito F, Fronza G. Menichini P, et al. Cells. 2021 Jan 7;10(1):98. doi: 10.3390/cells10010098. Cells. 2021. PMID: 33430525 Free PMC article. Review.
Due to the crucial role of P53 in therapy response, several molecules have been developed to re-establish the wild-type P53 function to mutant P53. PRIMA-1 and its methylated form PRIMA-1(Met) (also named APR246) are capable of restoring the wild-type conformation t …
Due to the crucial role of P53 in therapy response, several molecules have been developed to re-establish the wild-type P53 function to muta …
PRIMA-1 and PRIMA-1(Met) (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies.
Perdrix A, Najem A, Saussez S, Awada A, Journe F, Ghanem G, Krayem M. Perdrix A, et al. Cancers (Basel). 2017 Dec 16;9(12):172. doi: 10.3390/cancers9120172. Cancers (Basel). 2017. PMID: 29258181 Free PMC article. Review.
Accordingly, reactivation of p53 appears as a quite promising pharmacological approach and, effectively, several attempts have been made in that sense. The most widely investigated compounds for this purpose are PRIMA-1 (p53 reactivation and induction of massive apoptosis …
Accordingly, reactivation of p53 appears as a quite promising pharmacological approach and, effectively, several attempts have been made in …
Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions.
Herzog TJ, Wahab SA, Mirza MR, Pothuri B, Vergote I, Graybill WS, Malinowska IA, York W, Hurteau JA, Gupta D, González-Martin A, Monk BJ. Herzog TJ, et al. Int J Gynecol Cancer. 2023 Nov 6;33(11):1733-1742. doi: 10.1136/ijgc-2023-004605. Int J Gynecol Cancer. 2023. PMID: 37931976 Free PMC article. Review.
We compared blinded independent centralized review and investigator-assessed progressive disease performance in the PRIMA/ENGOT-ov26/GOG-3012 trial examining niraparib monotherapy. METHODS: PRIMA/ENGOT-ov26/GOG-3012 was a randomized, double-blind phase 3 trial; pati …
We compared blinded independent centralized review and investigator-assessed progressive disease performance in the PRIMA/ENGOT-ov26/ …
On Ageing and Maturing.
Simkulet W. Simkulet W. J Med Ethics. 2023 Aug 8:jme-2023-109418. doi: 10.1136/jme-2023-109418. Online ahead of print. J Med Ethics. 2023. PMID: 37553223
Here I argue biological ageing, or the wear and tear normally associated with chronological ageing, is prima facie undesirable, but that maturing can be prima facie desirable....
Here I argue biological ageing, or the wear and tear normally associated with chronological ageing, is prima facie undesirable, but t …
Cholinesterases in Tripartite Neuromuscular Synapse.
Petrov KA, Proskurina SE, Krejci E. Petrov KA, et al. Front Mol Neurosci. 2021 Dec 23;14:811220. doi: 10.3389/fnmol.2021.811220. eCollection 2021. Front Mol Neurosci. 2021. PMID: 35002624 Free PMC article. Review.
ACh action is terminated by acetylcholinesterase (AChE), anchored by collagen Q (ColQ) in the basal lamina of NMJs. AChE is also anchored by a proline-rich membrane anchor (PRiMA) to the surface of the nerve terminal. Butyrylcholinesterase (BChE), a second cholinesterase, …
ACh action is terminated by acetylcholinesterase (AChE), anchored by collagen Q (ColQ) in the basal lamina of NMJs. AChE is also anchored by …
4,226 results